• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Guardion Health Sciences Inc.

    2/28/22 4:11:51 PM ET
    $GHSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GHSI alert in real time by email
    SC 13G 1 ea156211-13gintra_guardion.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Guardion Health Sciences, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    40145Q401

    (CUSIP Number)

     

    February 18, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 7

     

     

    CUSIP No. 40145Q401  

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization United States of America
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 5,000,000
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 5,000,000
           

    9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,000,000 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 8.1% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  

     

    Page 2 of 7

     

     

    CUSIP No. 40145Q401  

     

    1. Names of Reporting Persons.
       
      Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization United States of America
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 5,000,000
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 5,000,000
           

    9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,000,000 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 8.1% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  

     

    Page 3 of 7

     

     

    CUSIP No. 40145Q401  

     

    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization Delaware
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 5,000,000
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 5,000,000
           

    9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,000,000 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 8.1% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      OO  

     

    Page 4 of 7

     

     

    Item 1.

     

    (a) Name of Issuer

     

    Guardion Health Sciences, Inc. (the “Issuer”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    2925 Richmond Avenue, Suite 1200

    Houston, Texas 77098

    Item 2.

     

    (a) Name of Person Filing

    (b) Address of Principal Business Office or, if none, Residence

    (c) Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 425 Joe Pye Lane, Walland, Tennessee 37886.

     

    (d) Title of Class of Securities

     

    Common Stock, $0.0001 par value per share, of the Issuer (the “Common Stock”).

     

    (e) CUSIP Number

     

    40145Q401

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on February 18, 2022 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on February 23, 2022), each of the Reporting Persons may have been deemed to have beneficial ownership of 2,711,094 shares of Common Stock, which consisted of (i) 2,500,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 211,094 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 24,426,993 shares of Common Stock outstanding as of February 16, 2022 as reported by the Issuer, plus (2) 2,500,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 211,094 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 2,288,906 shares of Common Stock issuable upon exercise of Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock and (II) 2,500,000 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 7,500,000 shares of Common Stock.

     

    Page 5 of 7

     

     

    (ii) As of the close of business on February 28, 2022, each of the Reporting Persons may have been deemed to have beneficial ownership of 5,000,000 shares of Common Stock, which consisted of: (i) 2,500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (ii) 2,500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represented beneficial ownership of approximately 8.1% of the Common Stock, based on (1) 24,426,993 shares of Common Stock outstanding as of February 16, 2022 as reported by the Issuer, plus (2) 32,550,000 issued at the closing of the transaction contemplated by the SPA, (3) 2,500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (4) 2,500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:      0     .

     

    (ii) Shared power to vote or to direct the vote:      5,000,000     .

     

    (iii) Sole power to dispose or to direct the disposition of      0     .

     

    (iv) Shared power to dispose or to direct the disposition of      5,000,000     .

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 6 of 7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 28, 2022  
       
      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 7 of 7

     

     

    Get the next $GHSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GHSI

    DatePrice TargetRatingAnalyst
    3/8/2022$0.60Buy
    Maxim Group
    More analyst ratings

    $GHSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Guardion Health Sciences with a new price target

      Maxim Group initiated coverage of Guardion Health Sciences with a rating of Buy and set a new price target of $0.60

      3/8/22 8:54:48 AM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    SEC Filings

    See more
    • Guardion Health Sciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)

      11/18/24 4:44:01 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)

      10/31/24 5:07:48 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25 filed by Guardion Health Sciences Inc.

      25 - Guardion Health Sciences, Inc. (0001642375) (Filer)

      10/11/24 3:45:50 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    Leadership Updates

    Live Leadership Updates

    See more

    $GHSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Guardion Health Sciences Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEO

      Plan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its intent to delist its common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. Guardion expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of the Common Stock on or about October 11, 2024 and to suspend trading of its Common Stock on the Nas

      10/1/24 9:00:00 AM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall as President and Chief Executive Officer

      HOUSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that Janet ("Jan") Hall has been appointed as the Company's new President and Chief Executive Officer. Ms. Hall is assuming these executive positions from Bret Scholtes, who has served in those positions since January 6, 2021. Mr. Scholtes is resigning effective June 9, 2023, and is also concurrently resigning from the Board of Directors of the Company. Ms.

      5/30/23 8:00:00 AM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AgEagle Announces Appointment of Kelly Anderson, CPA to the Board of Directors

      AgEagle Announces Appointment of Kelly Anderson, CPA to the Board of DirectorsWICHITA, KS / ACCESSWIRE / December 7, 2022 / AgEagle Aerial Systems Inc. (NYSE:UAVS) ("AgEagle" or the "Company"), an industry-leading provider of full stack flight hardware, sensors and software for commercial and government/defense use, today announced the appointment of Kelly Anderson, CPA as a new independent member of AgEagle's Board of Directors, effective today, December 5, 2022. Anderson will also serve as Chairperson of the Audit Committee and as a member of both the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective December 5, 2022."We are very pleased to we

      12/7/22 8:30:00 AM ET
      $FAF
      $FSR
      $GHSI
      $TOMZ
      Specialty Insurers
      Finance
      Auto Manufacturing
      Consumer Discretionary
    • Guardion Health Sciences Announces Filing of Certificate of Dissolution

      HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the "Effective Date"). The filing of the certificate was made pursuant to the terms of the Company's Plan of Liquidation and Dissolution (the "Plan") approved by stockholders at the Company's special meeting of stockholders held on May 31, 2024. As of October 30, 2024, Guardion has closed its stock transfer books, and record holders of shares of the Company's common stock, par value $0.001 per

      10/30/24 5:37:00 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEO

      Plan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its intent to delist its common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. Guardion expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of the Common Stock on or about October 11, 2024 and to suspend trading of its Common Stock on the Nas

      10/1/24 9:00:00 AM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock

      HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024. Forward-Looking Statements The matters described herein may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions re

      8/21/24 4:05:00 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    Financials

    Live finance-specific insights

    See more
    • Guardion Health Sciences Announces Filing of Certificate of Dissolution

      HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the "Effective Date"). The filing of the certificate was made pursuant to the terms of the Company's Plan of Liquidation and Dissolution (the "Plan") approved by stockholders at the Company's special meeting of stockholders held on May 31, 2024. As of October 30, 2024, Guardion has closed its stock transfer books, and record holders of shares of the Company's common stock, par value $0.001 per

      10/30/24 5:37:00 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock

      HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024. Forward-Looking Statements The matters described herein may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions re

      8/21/24 4:05:00 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024

      Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers science-based, clinically supported products designed for consumer ocular health, today announced its financial results for the three months and six months ended June 30, 2024, as described below. The Company also provided an update to stockholders of significant recent developments. Recent Developments: Sale of Viactiv® Brand and Business On May 31, 2024, as previously disclosed publicly, the Company completed the sale of all of t

      8/13/24 4:35:00 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Guardion Health Sciences Inc.

      SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)

      11/8/24 3:46:07 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Guardion Health Sciences Inc.

      SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)

      8/28/24 4:06:01 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Guardion Health Sciences Inc. (Amendment)

      SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)

      2/6/24 10:19:56 AM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Radoff Bradley Louis sold $1,626,419 worth of shares (115,540 units at $14.08), decreasing direct ownership by 48% to 112,414 units (SEC Form 4)

      4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)

      8/28/24 4:11:39 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Great Point Capital Llc claimed ownership of 159,652 units of Guardion Health Sciences (SEC Form 3)

      3 - Guardion Health Sciences, Inc. (0001642375) (Issuer)

      4/3/24 12:54:58 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Cox Katharine Joan

      3 - Guardion Health Sciences, Inc. (0001642375) (Issuer)

      8/7/23 8:47:26 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care